Simon Høj

Simon Høj

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
ANAmalie Ying Nielsen
Amalie Ying Nielsen
SHSimon Høj
Simon Høj
STSimon Francis Thomsen
Simon Francis Thomsen
HMHowraman Meteran
Howraman Meteran
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 20% of children and 10% of adults worldwide. Current research suggests a correlation between serum vitamin D level and AD severity and that vitamin D supplementation could have a potential therapeutic effect on AD. Objectives: To conduct a systematic review and meta-analysis of studies of vitamin D supplementation for disease improvement in children and adults with AD. Methods: PubMed, EMBASE, and Cochrane were searched from 19 April to 20 April 2024. We included randomized controlled trials (RCTs) of patients with AD comparing an intervention group with a control group. The risk of bias of the selected studies was assessed using the Cochrane risk-of-bias tool for randomized trials. All analyses were conducted in R (v4.1.2; R Core Team 2021). Results: Eleven RCTs with 686 participants were included. The included trials had measured AD severity by using the SCOring Atopic Dermatitis (SCORAD) or the Eczema Area and Severity Index (EASI). Vitamin D supplementation significantly reduced AD severity compared with the control group (standardized mean difference = −0.41, 95% CI: −0.67 to −0.16, I2 = 58%, p < 0.01). Conclusions: Vitamin D supplementation reduces AD severity in children and adults. Larger-scale and longer-term studies are still needed to confirm this conclusion. This study has been registered on PROSPERO (CRD42024535014).

28 August 2024 in Journal of Allergy and Clinical Immunology: Global
Verified
Journal Article
Open access
SHSimon Høj
Simon Høj
STSimon Francis Thomsen
Simon Francis Thomsen
CUCharlotte Suppli Ulrik
Charlotte Suppli Ulrik
HMHanieh Meteran
Hanieh Meteran
TSTorben Sigsgaard
Torben Sigsgaard
HMHowraman Meteran
Howraman Meteran
This study assessed the reliability of ChatGPT as a source of information on asthma, given the increasing use of artificial intelligence-driven models for medical information. Prior concerns about misinformation on atopic diseases in various digital platforms underline the importance of this evaluation. We aimed to evaluate the scientific reliability of ChatGPT as a source of information on asthma. The study involved analyzing ChatGPT's responses to 26 asthma-related questions, each followed by a follow-up question. These encompassed definition/risk factors, diagnosis, treatment, lifestyle factors, and specific clinical inquiries. Medical professionals specialized in allergic and respiratory diseases independently assessed the responses using a 1-to-5 accuracy scale. Approximately 81% of the responses scored 4 or higher, suggesting a generally high accuracy level. However, 5 responses scored >3, indicating minor potentially harmful inaccuracies. The overall median score was 4. Fleiss multirater kappa value showed moderate agreement among raters. ChatGPT generally provides reliable asthma-related information, but its limitations, such as lack of depth in certain responses and inability to cite sources or update in real time, were noted. It shows promise as an educational tool, but it should not be a substitute for professional medical advice. Future studies should explore its applicability for different user demographics and compare it with newer artificial intelligence models.

15 November 2023 in Journal of Public Health
Verified
Journal Article
Closed access
PDF file
SHSimon Høj
Simon Høj
STSimon F Thomsen
Simon F Thomsen
HMHanieh Meteran
Hanieh Meteran
TSTorben Sigsgaard
Torben Sigsgaard
HMHowraman Meteran
Howraman Meteran
Background: Optimal management of allergic rhinitis requires patient education with easy access to accurate information. However, previous online platforms have provided misleading information. The demand for online medical information continues to grow, especially with the introduction of advanced chatbots like ChatGPT. Methods: This study aimed to evaluate the quality of information provided by ChatGPT regarding allergic rhinitis. A Likert scale was used to assess the accuracy of responses, ranging from 1 to 5. Four authors independently rated the responses from a healthcare professional’s perspective. Results: A total of 20 questions covering various aspects of allergic rhinitis were asked. Among the answers, eight received a score of 5 (no inaccuracies), five received a score of 4 (minor non-harmful inaccuracies), six received a score of 3 (potentially misinterpretable inaccuracies) and one answer had a score of 2 (minor potentially harmful inaccuracies). Conclusions: The variability in accuracy scores highlights the need for caution when relying solely on chatbots like ChatGPT for medical advice. Patients should consult qualified healthcare professionals and use online sources as a supplement. While ChatGPT has advantages in medical information delivery, its use should be approached with caution. ChatGPT can be useful for patient education but cannot replace healthcare professionals.

15 May 2025 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
SHSimon Høj
Simon Høj
VBVibeke Backer
Vibeke Backer
LHLaura Høj
Laura Høj
TSTorben Sigsgaard
Torben Sigsgaard
HMHowraman Meteran
Howraman Meteran

28 May 2025 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
SHSimon Høj
Simon Høj
FNFrederik Kronvold Nielsen
Frederik Kronvold Nielsen
Bo ChawesBo Chawes
Bo Chawes
VBVibeke Backer
Vibeke Backer
Allan LinnebergAllan Linneberg
Allan Linneberg
HMHowraman Meteran
Howraman Meteran

20 November 2025 in Current Allergy and Asthma Reports
Verified
Journal Article
Open access
PDF file
CPChristian K. Pedersen
Christian K. Pedersen
VBVibeke Backer
Vibeke Backer
JTJens Even Tidemandsen
Jens Even Tidemandsen
SHSimon Høj
Simon Høj
MHMarie Høxbro
Marie Høxbro
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
Purpose of Review Smell loss is among the most debilitating symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to synthesize current evidence on the smell-restoring efficacy of biologics, focusing on outcomes measured by psychophysical tests. Recent Findings Biologics mark a paradigm shift in the management of refractory CRSwNP, offering targeted, effective and safe treatment options. However, their relative impact on psychophysical smell outcomes remains uncertain. With several biologics now approved and real-world evidence emerging, a comprehensive evaluation is needed. Summary This is a systematic review and meta-analysis of 8 RCTs (n = 2,024) and an additional review of 20 cohorts (n = 1,685). Among RCTs, biologic treatment produced a moderate to large pooled improvement in psychophysical smell scores (standardized mean difference, [SMD] = 0.72 (95% CI 0.32–1.13), p = 0.0004). The effect differed between drugs (χ² = 23.95, p < 0.0002). Dupilumab showed the largest improvements across four RCTs (SMD = 1.16, 95% CI = 0.35–1.97). In single RCTs, benralizumab showed large effect (1.03, 0.55–1.51), tezepelumab (0.56, 0.46–0.67), telikibart (0.35, 0.11–0.59), and omalizumab (0.27, 0.15–0.40) yielded modest but significant improvements. Mepolizumab showed no effect (0.1330 (95% CI −0.2490–0.5150). Blood-eosinophil level correlated with treatment response (p < 0.001). The cohort studies supported the findings (SMD = 1.20, 95% CI = 0.99–1.42), though most data were derived from studies of dupilumab. Overall, biologics substantially improve psychophysically measured olfactory function in CRSwNP. Future head-to-head trials are warranted to delineate comparative efficacy of smell recovery.